Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
GlaxoSmithKline, Merck Sharp & Dohme Corp., and AstraZeneca
There will be an estimated 21,410 new cases of ovarian cancer this
year in the United States, and an estimated 13,770 deaths due to
ovarian cancer in the US, according to the American Cancer Society.
Ovarian cancer is usually found late, stage 3 or higher, where it
has already spread or metastasized to other parts of the abdomen, or
worse. This is due in large part to a lack of symptoms during the
earlier stages. The five year survival rate is only 45%. Fortunately
for patients with ovarian cancer, the treatment paradigm has
exploded in the past three years, giving medical directors and
clinicians more options in managing patients with ovarian cancer.
Leading the way in new options for ovarian cancer are poly
(ADP-ribose) polymerase (PARP) inhibitors, which have shown improved
efficacy for patients with ovarian cancer. Additionally, new
indications for these targeted agents offer expanded options in the
maintenance setting in varying lines of therapy. It is important for
medical directors, oncologists, and nurses who manage ovarian cancer
patient populations to have a solid understanding of the mechanistic
rationale for the use of these medications in order to optimize
their therapeutic application.
The enzyme poly (ADP-ribose) polymerase (PARP) is a critical
component of DNA base excision repair, essential for the repair of
single-strand breaks in DNA. If the action of PARP is inhibited in a
normal cell, these breaks are converted to double-strand breaks and
repaired through the process of homologous recombination. However,
in cells with pre-existing defects in the homologous recombination
DNA repair pathway, such as in cancer cells harboring BRCA1/2
mutations, inhibition of PARP results in synthetic lethality.
Exploitation of this deficiency with PARP inhibitors creates a
therapeutic opportunity for tumor cell-specific cell killing.
Challenges associated with maximizing therapeutic outcomes with
potential PARP inhibitor use in ovarian cancer include selection of
optimal testing strategies to personalize care, management of
treatment toxicities, and development of evidence-based sequencing
and combination strategies. With new indications for these newer
treatments have been approved, including new indications, making the
need for education extremely important. It is for this reason that
we must educate healthcare professionals on the latest clinical
data, updated guidelines, and management strategies to improve
clinical and economic outcomes.
Upon completion of this
activity, participants will be able to:
Outline the clinical and
socioeconomic burdens of ovarian cancer and the goals of
remission maintenance that can be addressed by clinical pathways
Explore the role of the DNA damage
response (DDR) pathway in tumor suppression and describe how
mutations in DDR genes lead to tumor proliferation
Compare and contrast safety and
efficacy outcomes from recent pivotal trials on PARP inhibitors
in ovarian cancer, with a close look at the maintenance setting
Examine the role of PARP inhibitors
as a first-line maintenance therapy for patients with advanced
Define strategies for anticipating,
recognizing, and managing adverse events of PARP inhibitor
therapy in patients with ovarian cancer
Apply methods to enable optimal cost
management of PARP inhibitors to be realized by multiple ovarian
cancer stakeholders including managed care organizations
||Richard T. Penson, MD,
Associate Professor of Medicine Harvard Medical School
Clinical Director Medical Gyn Onc at Massachusetts
IRB Chair, Dana-Farber / Harvard Cancer Center
has served as a researcher for Genetech, Inc.,
AstraZeneca, Eisai, Amgen, Inc, Vascular Biogenics Ltd,
Array BioPharma, and Sanofi-Aventis US LLC. Dr. Penson
has held positions on the scientific advisory boards for
Genetech, Inc., AstraZeneca, Eisai, Inc, Amgen, Inc.,
Clovis Oncology, Vascular Biogenetics Ltd, AbbVie,
Tesaro, Merck & Co, Sutro BioPharma, Mersana
Therapeutics, New Line. His presentation has been
reviewed for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
GlaxoSmithKline, Merck Sharp & Dohme Corp., and AstraZeneca
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue